Anidulafungin (previously known as LY303366 and briefly also referred to as VER-002 and V-echinocandin) is a glucan synthesis inhibitor of the echinocandin structural class. It is composed of the echinocandin B nucleus with a terphenyl head group and a C5 tail.

Anidulafungin has been developed by Eli Lilly Pharmaceuticals. It has recently been licensed to Versicor for development as a parenteral agent. It is currently in clinical trials. Its trade name has not been announced.





As with other echinocandins, anidulafungin blocks the synthesis of a major fungal cell wall component, 1-3-beta glucan, presumably via inhibition of 1,3-beta-glucan synthase [1143].



Anidulafungin is active in vitro against Candida spp. However, anidulafungin MICs for C. parapsilosis and C. guilliermondii are relatively higher than those for the other species. It has been shown to be fungicidal against some isolates of C. albicans and C. glabrata [1609] [2066].

Anidulafungin does not have significant activity against Cryptococcus neoformans. Similarly, its activity against Blastomyces dermatitidis, Sporothrix schenckii, Trichosporon beigelii, Acremonium strictum, Rhizopus arrhizus, Fusarium spp. and Phialophora spp. is limited. Anidulafungin MICs for Histoplasma capsulatum, Cladophialophora bantiana, Pseudallescheria boydii, and Bipolaris spp. are also relatively high [616] [2066].

As with caspofungin, activity of anidulafungin against Aspergillus spp. has been investigated by using a distinctive parameter, "minimum effective concentration" (MEC), as well as MIC [1145]. Anidulafungin MECs for Aspergillus are in an acceptable range and lower than the MICs [1607] [1502].

For anidulafungin MICs obtained for various types of fungi, see susceptibility patterns and the susceptibility database.



Typical doses for anidulafungin are not yet known.


Results of the clinical trials have not yet been reported.



It has oral and intravenous formulations.



Anidulafungin is undergoing Phase II clinical trials.